ABT
T2Abbott Laboratories
Biotech '26: Established PharmaChild Care '24: Child HealthcareData Owners '25: Healthcare, Claims & Clinical DataMedTech Long '26: Diagnostics & Early Detection
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-16 | Abbott reported strong Q2'26 results with accelerated sales growth and an EPS beat, leading to raised full-year EPS guidance. Management expressed high confidence in H2 acceleration driven by Nutrition, EP, Core Lab, and Cancer Diagnostics, alongside a robust pipeline. The market reacted very positively, with the stock gaining 12.78% (outperforming SPY), aligning with the optimistic outlook and strong guidance. | Earnings Transcript | Positive | +12.78% (vs SPY: +14.31%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ABT_ba778762 | could happen in the fall | 2026-09-01 | 2026-11-30 | Medicare reimbursement expansion for continuous glucose monitoring (CGM) for Type 2 non-insulin users in the US. | This represents a multibillion-dollar opportunity, unlocking coverage for approximately 10 million Medicare beneficiaries and accelerating commercial insurance adoption, which is expected to significantly boost CGM sales. | Ticker | 2026-07-16 | earnings_transcript |
| ABT_6009f906 | in the fall | 2026-09-01 | 2026-11-30 | International rollout of Libre Duo, the world's first dual glucose ketone monitoring sensor. | The introduction of this innovative new technology internationally is expected to contribute to the growth and leadership of Abbott's diabetes care business. | Ticker | 2026-07-16 | earnings_transcript |
| ABT_30e24e43 | potential to be able to get this approved by year end | 2026-10-01 | 2026-12-31 | FDA approval for the new Amulet 360 left atrial appendage device. | This approval enables a significant relaunch of a superior product in the $2 billion LAA closure market, positioning Abbott for substantial market share capture in the electrophysiology business. | Ticker | 2026-07-16 | earnings_transcript |
| ABT_e32745b9 | in the third quarter | 2026-07-01 | 2026-09-30 | Transition from limited market release to full market release of the Bolt 2.0 PFA catheter in the US. | This full market release is expected to accelerate Abbott's growth trajectory and help the company outperform the market and recapture share in the electrophysiology segment. | Ticker | 2026-07-16 | earnings_transcript |